Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 1 / Phase 2INTERVENTIONAL

Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis

A Randomized, Double-Blind, Controlled Trial Evaluating the Potential of Mesenchymal Stem Cells and Their Secretome as Adjuvant Therapy to Reduce Length of Hospital Stay and Mortality in Patients With Sepsis Due to Pneumonia

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study was conducted to determine the effect of Umbilical Cord Mesenchymal Stem Cell (UC-MSC) and Secretome in severe ARDS patients. The study is a randomized control trial - double blind, which has 3 arms intervention namely, Control treatment, UC-MSC treatment, and UC-MSC and Secretome treatment.

Who May Be Eligible (Plain English)

Who May Qualify: - Male or female at least 40 years old when the willing to sign a consent form Form (ICF) is signed by the family, as evidenced by an identity card. - Patients with severe ARDS according to Berlin criteria - Families are willing to participate in clinical trial procedures including not participating in other clinical trials for the duration of participation. Who Should NOT Join This Trial: - A pregnant woman is proven by a pregnancy test. - The results of the SGOT or SGPT examination increased \> 5 times the upper limit of the normal laboratory value in the hospital. - Estimated glomerular filtration rate (eGFR) \< 30 ml/min, including patients undergoing routine hemodialysis. - Having more than 2 of the following co-morbidities; hypertension, diabetes, chronic heart disease, chronic lung disease, COPD, asthma, tuberculosis, cancer, chronic kidney disease, immunosuppressive disease, HIV. - The results of the lipid profile are far above normal (what is the cut off number?). Normal cholesterol levels for women aged 20 years and over are 125-200 mg/dL with LDL below 100 mg/dL and HDL above 40 mg/dL. It is said to have high cholesterol when the level in the blood reaches more than 239 mg/dL. Normal cholesterol levels for men aged 20 years or older are 125-200 mg/dL with LDL below 100 mg/dL and HDL above 40 mg/dL. It is said to have high cholesterol when the level in the blood reaches more than 239 mg/dL. - PT APTT, C Peptide Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Male or female at least 40 years old when the Informed Consent Form (ICF) is signed by the family, as evidenced by an identity card. * Patients with severe ARDS according to Berlin criteria * Families are willing to participate in clinical trial procedures including not participating in other clinical trials for the duration of participation. Exclusion Criteria: * A pregnant woman is proven by a pregnancy test. * The results of the SGOT or SGPT examination increased \> 5 times the upper limit of the normal laboratory value in the hospital. * Estimated glomerular filtration rate (eGFR) \< 30 ml/min, including patients undergoing routine hemodialysis. * Having more than 2 of the following co-morbidities; hypertension, diabetes, chronic heart disease, chronic lung disease, COPD, asthma, tuberculosis, cancer, chronic kidney disease, immunosuppressive disease, HIV. * The results of the lipid profile are far above normal (what is the cut off number?). Normal cholesterol levels for women aged 20 years and over are 125-200 mg/dL with LDL below 100 mg/dL and HDL above 40 mg/dL. It is said to have high cholesterol when the level in the blood reaches more than 239 mg/dL. Normal cholesterol levels for men aged 20 years or older are 125-200 mg/dL with LDL below 100 mg/dL and HDL above 40 mg/dL. It is said to have high cholesterol when the level in the blood reaches more than 239 mg/dL. * PT APTT, C Peptide

Treatments Being Tested

OTHER

Control (NaCl 0.9%)

Standard of Care (SoC) + IV placebo (NaCl 0.9%) on the 2nd, 5th, 8th day + nasal drop 2 mL (growth medium) on the 1st, 4th, 7th day.

BIOLOGICAL

UC-MSC

Standard of Care (SoC) + IV 10 million kg/body weight UC-MSC on the 2nd, 5th, 8th day + nasal drop 2 mL (growth medium) on the 1st, 4th, 7th day.

BIOLOGICAL

UC-MSC and Secretome

Standard of Care (SoC) + IV 10 million kg/body weight UC-MSC on the 2nd, 5th, 8th day + nasal drop 2 mL of Secretome on the 1st, 4th, 7th day.

Locations (1)

RSPAD Gatot Soebroto
Jakarta Pusat, DKI Jakarta, Indonesia